SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending amidst community excitement surrounding upcoming airdrops, burns, and staking features, with some eyeing a $3.5M market cap giveaway. The community emphasizes organic growth, strong holder conviction, and the project's commitment to community-driven development on the Solana blockchain.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

ASST is trending due to its merger with Strive Enterprises and subsequent plans for a Bitcoin treasury, leading to speculation of a potential short squeeze. The community is drawing comparisons to similar plays like QMMM and OCTO, fueled by high short interest and the backing of notable investors. Some traders are setting high price targets, while others caution against expecting gains beyond a certain level due to potential dilution.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is gaining attention as a corporate treasury asset, potentially outperforming Bitcoin and Ethereum. Community members are highlighting its staking opportunities and ecosystem growth. Despite some volatility, the overall sentiment suggests optimism for a potential rally.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty is trending as the community buzzes about airdrops and the upcoming launch of its own DEX in November. The development team is also building a trading bot, adding to the excitement around this project. Discussions suggest a strong community backing and anticipation for future developments in the meme coin space.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as traders discuss the implications of the special warrant dividend and a profitable quarter, with some speculating about a potential short squeeze. Community members are analyzing how the warrants could impact short sellers and whether it will expose synthetic shares. The conversation also includes potential price targets and the possibility of a "double squeeze" scenario.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a trading halt in Singapore, sparking speculation about an upcoming announcement; community discussions range from potential partnerships to dilution concerns. Traders are weighing whether the news will be positive or negative for the EV manufacturer, as some point to broader market factors influencing the stock.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CWD is trending as traders discuss its volatile price action, drawing comparisons to other high-flying stocks. Community members are pointing to the company's digital asset treasury diversification plan, while others speculate about a potential short squeeze. Some traders are also noting the stock's low float and high short interest as factors driving the conversation.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to speculation around a new crypto treasury strategy, mirroring the recent moves of other high-flying stocks. The community is drawing comparisons to CWD's previous surge and anticipates a similar explosive run. Intense volatility and overnight pricing are also key discussion points.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following its earnings report, with community discussions focusing on the massive increase in remaining performance obligations (RPO) and future growth forecasts, despite missing on current earnings. Bulls are excited about the potential for AI-driven cloud revenue, while bears question the achievability of long-term projections and the validity of backlog accounting. The overall sentiment is highly volatile, with significant debate around whether this move is justified or indicative of a market bubble.

American Bitcoin Corp. is a bitcoin accumulation platform focused on building America's bitcoin infrastructure platform. It delivers institutional-grade exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded on October 22, 2020 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail investor chatter around Celldex Therapeutics spiked on Sunday following new Phase 2 data showing barzolvolimab provided “profound long-term” relief from angioedema in patients with chronic spontaneous urticaria (CSU).Celldex shares closed 4.5% higher at $21.26 on Friday.The company presented updated 52-week results at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow, showing that 77% of patients on barzolvolimab were angioedema-free at Week 52.&nbsp;The antibody therapy also showed up to 87% of patients reported “clinically meaningful” improvements in angioedema activity scores (AAS7).Barzolvolimab targets KIT, a receptor tyrosine kinase involved in mast cell regulation.&nbsp;In CSU, mast cells drive persistent inflammation and swelling even after standard antihistamine therapy fails.Patients with severe CSU and angioedema frequently endure disfigurement and debilitating pain, said Diane C. Young, MD, Chief Medical Officer at Celldex.&nbsp;Additional data showed an 86% mean reduction in angioedema activity in the 150 mg group and 82% in the 300 mg every-8-weeks group.&nbsp;Patients remained angioedema-free for 72% of the year-long treatment period.Retail sentiment on platforms such as Stocktwits and Reddit turned sharply bullish over the weekend, with several users highlighting the durability of symptom control and potential differentiation from existing CSU treatments like Novartis’ Xolair.The 208-patient Phase 2 trial had previously met all primary and secondary endpoints at 12 weeks.&nbsp;A global Phase 3 program is underway, targeting antihistamine-refractory CSU patients, including those previously treated with biologics.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.Celldex stock has declined 17.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

Latest Ratings for CLDX
 DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
 View More...

Analyst Expectations For Celldex Therapeutics's Future

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Current Price	$24.30
Prev Close	$23.40
Open	$23.51
Dividend Yield	0.00%
50-Day Moving Average	$22.45
Beta	1.10
Avg. Volume	1.47M
PE Ratio	-7.78

52-Week High	$47.00
52-Week Low	$14.40
Market Capitalization	$1.55B
EPS (Annual)	-$2.45
Price to Book	2.37
Revenue Per Employee	$37,741.93
Enterprise Value/EBITDA	N/A

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDX Celldex Therapeutics Inc.